Compare Amphastar Pharmaceuticals Inc (AMPH) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs ProShares Ultra QQQ ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while ProShares Ultra QQQ ETF trades at $92.14. The key difference: ProShares Ultra QQQ ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | QLD | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $30.81 | $100.53 |
52-Week Low | $16.87 | $57.16 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
QLD trades at $93.70, up 0.59% with a bullish technical signal from moving averages. The ProShares Ultra QQQ ETF leverages Nasdaq-100 exposure, delivering over 10,000% total return since inception. Recent news highlights tech sector strength and QLD's role in growth portfolios. Support levels at $92 and resistance at $94 indicate tight trading range.
Outlook remains positive given tech earnings momentum and AI-driven market optimism. However, leveraged ETF structure amplifies volatility risks, with QLD experiencing 63.80% maximum drawdown historically. Investors should weigh amplified returns against heightened downside exposure in market corrections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
